AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 08/21/23

2023-08-21 16:01:59 ET Are you on the hunt for the most promising penny stocks to invest in for 2023? Join the ever-expanding group of investors who are keen to leverage the booming market. With record-breaking performances by the S&P 500 and Nasdaq this year, there’s a growi...

2023-08-07 14:08:45 ET Investors often rely on stock market news to stay abreast of everything, ranging from low-cost penny stocks to industry giants such as Apple or Tesla. It’s no secret that news can ignite excitement and skepticism in the blink of an eye, fueling speculation ...

2023-08-04 15:59:06 ET Amneal Pharmaceuticals, Inc. (AMRX) Q2 2023 Earnings Conference Call August 4, 2023 08:30 ET Company Participants Anthony DiMeo - Head, Investor Relations Chirag Patel - Co-Founder and Co-Chief Executive Officer Chintu Patel - Co-Founder an...

2023-08-04 10:09:12 ET Gainers: Alector ( ALEC ) +22% . OraSure Technologies ( OSUR ) +21% . Amneal Pharmaceuticals ( AMRX ) +20% . iRhythm Technologies ( IRTC ) +20% . Natera ( NTRA ) +16% . Losers: Mesoblast ( MESO ) ...

2023-08-04 06:03:20 ET Amneal Pharmaceuticals press release ( NYSE: AMRX ): Q2 Non-GAAP EPS of $0.19 beats by $0.09 . Revenue of $599M (+7.2% Y/Y) beats by $33.89M . FY23 Outlook: Net revenue of $2.3B-$2.4B from prior guidance of $2.25-$2.35B Adj EPS of...

‒ Q2 2023 Net Revenue of $599 million; GAAP Net Income of $12 million; Diluted EPS of $0.08 ‒ ‒ Q2 2023 Adjusted Net Income (1) of $57 million; Adjusted EBITDA (1) of $146 million; Adjusted Diluted EPS (1) of $0.19 ‒ ‒ Raising 2023 Fu...

2023-08-03 14:20:38 ET Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q2 earnings results on Friday, August 4th, before market open. The consensus EPS Estimate is $0.10 (-47.4% Y/Y) and the consensus Revenue Estimate is $565.11M (+1.1% Y/Y). Over the la...

- Represents three high-value medicines across complex dosage forms Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced it has submitted Abbreviated New Drug Applications (“ANDA”) to the U.S. Food and Drug Adm...

2023-07-10 08:00:00 ET Summary A Complete Response Letter from the FDA temporarily tanked AMRX stock. New launches and established products should contribute to Amneal Pharmaceuticals' Q2 growth. A generic to blockbuster sets Amneal up nicely for Q3 and onward. July ...

NEW YORK, NY / ACCESSWIRE / July 9, 2023 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") (NYSE:AMRX). Investors who purchased Amneal securities are encouraged to obtain additional infor...